US 12,448,622 B2
Oligonucleotides
Michael Gantier, McKinnon (AU)
Assigned to Hudson Institute of Medical Research, Clayton (AU)
Filed by HUDSON INSTITUTE OF MEDICAL RESEARCH, Clayton (AU)
Filed on Jun. 22, 2023, as Appl. No. 18/213,116.
Application 18/213,116 is a continuation of application No. 17/926,383, previously published as PCT/AU2021/050469, filed on May 19, 2021.
Claims priority of application No. 2020901606 (AU), filed on May 19, 2020.
Prior Publication US 2024/0287510 A1, Aug. 29, 2024
Int. Cl. C12N 15/113 (2010.01); A61K 45/06 (2006.01); C12N 15/11 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 45/06 (2013.01); C12N 15/111 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/344 (2013.01); C12N 2320/53 (2013.01)] 19 Claims
 
1. An oligonucleotide, comprising a 5′ region comprising at least five modified nucleotides, wherein the 5′ end consists of terminal 5′-mUmC-3′ or terminal 5′-mCmU-3′,
a middle region comprising a stretch of ten nucleotides wherein each nucleotide comprises a 3′-5′ phosphorothioate internucleotide linkage, and
a 3′ region comprising at least five modified nucleotides,
wherein each modified nucleotide comprises a 2′-O-methyl sugar and a 3′-5′ phosphorothioate internucleotide linkage,
wherein mU comprises 2′-O-methyl uridine and a 3′-5′ phosphorothioate internucleotide linkage, and mC comprises 2′-O-methyl cytidine and a 3′-5′ phosphorothioate internucleotide linkage,
wherein the oligonucleotide is between about 20 and about 50 nucleotides in length, and wherein the oligonucleotide potentiates Toll-like receptor 8 (TLR8) activity.